460 related articles for article (PubMed ID: 29681511)
1. A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment.
Griveau A; Seano G; Shelton SJ; Kupp R; Jahangiri A; Obernier K; Krishnan S; Lindberg OR; Yuen TJ; Tien AC; Sabo JK; Wang N; Chen I; Kloepper J; Larrouquere L; Ghosh M; Tirosh I; Huillard E; Alvarez-Buylla A; Oldham MC; Persson AI; Weiss WA; Batchelor TT; Stemmer-Rachamimov A; Suvà ML; Phillips JJ; Aghi MK; Mehta S; Jain RK; Rowitch DH
Cancer Cell; 2018 May; 33(5):874-889.e7. PubMed ID: 29681511
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Yang HC; Wang JY; Bu XY; Yang B; Wang BQ; Hu S; Yan ZY; Gao YS; Han SY; Qu MQ
J Cell Physiol; 2019 May; 234(5):6783-6800. PubMed ID: 30317578
[TBL] [Abstract][Full Text] [Related]
3. Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas.
Kosty J; Lu F; Kupp R; Mehta S; Lu QR
Cell Cycle; 2017 Sep; 16(18):1654-1660. PubMed ID: 28806136
[TBL] [Abstract][Full Text] [Related]
4. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
5. Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression.
Reis M; Czupalla CJ; Ziegler N; Devraj K; Zinke J; Seidel S; Heck R; Thom S; Macas J; Bockamp E; Fruttiger M; Taketo MM; Dimmeler S; Plate KH; Liebner S
J Exp Med; 2012 Aug; 209(9):1611-27. PubMed ID: 22908324
[TBL] [Abstract][Full Text] [Related]
6. Can oligodendrocyte transcriptional factor-2 (Olig2) be used as an alternative for 1p/19q co-deletions to distinguish oligodendrogliomas from other glial neoplasms?
Kurdi M; Alkhatabi H; Butt N; Albayjani H; Aljhdali H; Mohamed F; Alsinani T; Baeesa S; Almuhaini E; Al-Ghafari A; Hakamy S; Faizo E; Bahakeem B
Folia Neuropathol; 2021; 59(4):350-358. PubMed ID: 35114775
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Tomar VS; Patil V; Somasundaram K
Cell Biol Toxicol; 2020 Jun; 36(3):273-278. PubMed ID: 31758290
[TBL] [Abstract][Full Text] [Related]
8. Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier.
Huang Y; Hoffman C; Rajappa P; Kim JH; Hu W; Huse J; Tang Z; Li X; Weksler B; Bromberg J; Lyden DC; Greenfield JP
Cancer Res; 2014 Feb; 74(4):1011-21. PubMed ID: 24371228
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.
Mo H; Magaki S; Deisch JK; Raghavan R
J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894
[TBL] [Abstract][Full Text] [Related]
10. WNT signaling suppresses oligodendrogenesis via Ngn2-dependent direct inhibition of Olig2 expression.
Jiang M; Yu D; Xie B; Huang H; Lu W; Qiu M; Dai ZM
Mol Brain; 2020 Nov; 13(1):155. PubMed ID: 33187539
[TBL] [Abstract][Full Text] [Related]
11. Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.
Lu F; Chen Y; Zhao C; Wang H; He D; Xu L; Wang J; He X; Deng Y; Lu EE; Liu X; Verma R; Bu H; Drissi R; Fouladi M; Stemmer-Rachamimov AO; Burns D; Xin M; Rubin JB; Bahassi EM; Canoll P; Holland EC; Lu QR
Cancer Cell; 2016 May; 29(5):669-683. PubMed ID: 27165742
[TBL] [Abstract][Full Text] [Related]
12. MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation.
Delic S; Lottmann N; Stelzl A; Liesenberg F; Wolter M; Götze S; Zapatka M; Shiio Y; Sabel MC; Felsberg J; Reifenberger G; Riemenschneider MJ
Neuro Oncol; 2014 Jan; 16(2):179-90. PubMed ID: 24305703
[TBL] [Abstract][Full Text] [Related]
13. Olig2 SUMOylation protects against genotoxic damage response by antagonizing p53 gene targeting.
Liu H; Weng W; Guo R; Zhou J; Xue J; Zhong S; Cheng J; Zhu MX; Pan SJ; Li Y
Cell Death Differ; 2020 Nov; 27(11):3146-3161. PubMed ID: 32483381
[TBL] [Abstract][Full Text] [Related]
14. Endothelial-like malignant glioma cells in dynamic three dimensional culture identifies a role for VEGF and FGFR in a tumor-derived angiogenic response.
Smith SJ; Ward JH; Tan C; Grundy RG; Rahman R
Oncotarget; 2015 Sep; 6(26):22191-205. PubMed ID: 26203665
[TBL] [Abstract][Full Text] [Related]
15. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.
Fu J; Koul D; Yao J; Wang S; Yuan Y; Colman H; Sulman EP; Lang FF; Yung WK
Cancer Res; 2013 May; 73(10):3062-74. PubMed ID: 23492364
[TBL] [Abstract][Full Text] [Related]
16. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
[No Abstract] [Full Text] [Related]
17. Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse.
Zhang L; He X; Liu X; Zhang F; Huang LF; Potter AS; Xu L; Zhou W; Zheng T; Luo Z; Berry KP; Pribnow A; Smith SM; Fuller C; Jones BV; Fouladi M; Drissi R; Yang ZJ; Gustafson WC; Remke M; Pomeroy SL; Girard EJ; Olson JM; Morrissy AS; Vladoiu MC; Zhang J; Tian W; Xin M; Taylor MD; Potter SS; Roussel MF; Weiss WA; Lu QR
Cancer Cell; 2019 Sep; 36(3):302-318.e7. PubMed ID: 31474569
[TBL] [Abstract][Full Text] [Related]
18. NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment.
Broggini T; Wüstner M; Harms C; Stange L; Blaes J; Thomé C; Harms U; Mueller S; Weiler M; Wick W; Vajkoczy P; Czabanka M
Cancer Lett; 2016 Oct; 380(2):568-576. PubMed ID: 26297987
[TBL] [Abstract][Full Text] [Related]
19. Invasion as limitation to anti-angiogenic glioma therapy.
Lamszus K; Kunkel P; Westphal M
Acta Neurochir Suppl; 2003; 88():169-77. PubMed ID: 14531575
[TBL] [Abstract][Full Text] [Related]
20. Age-Dependent Decline in Fate Switch from NG2 Cells to Astrocytes After Olig2 Deletion.
Zuo H; Wood WM; Sherafat A; Hill RA; Lu QR; Nishiyama A
J Neurosci; 2018 Feb; 38(9):2359-2371. PubMed ID: 29382710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
